Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 582 shares, a drop of 96.2% from the August 15th total of 15,394 shares. Based on an average daily trading volume, of 61,763 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are short sold.

Revelation Biosciences Stock Performance

Shares of REVB stock traded down $0.01 during midday trading on Thursday, hitting $0.99. 4,923 shares of the company were exchanged, compared to its average volume of 40,507. The firm has a market capitalization of $3.96 million, a P/E ratio of -0.08 and a beta of -0.14. The firm’s 50 day moving average price is $1.06 and its two-hundred day moving average price is $1.11. Revelation Biosciences has a 52 week low of $0.88 and a 52 week high of $8.40.

Revelation Biosciences (NASDAQ:REVB) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.01. Analysts expect that Revelation Biosciences will post -5.18 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, August 25th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC bought a new position in Revelation Biosciences during the 3rd quarter worth $114,000. Geode Capital Management LLC bought a new stake in shares of Revelation Biosciences in the fourth quarter valued at about $27,000. Finally, Sabby Management LLC grew its stake in shares of Revelation Biosciences by 192.5% in the fourth quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock valued at $484,000 after acquiring an additional 398,651 shares in the last quarter. 12.80% of the stock is owned by institutional investors and hedge funds.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.